Volume 18, Issue C, June 2017, Pages 66 - 68
Should a statin be given to all hypertensive patients?
Authors
Harry Struijker-Boudier
Department of Pharmacology and Toxicology, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands
E-mail address: h.struijkerboudier@maastrichtuniversity.nl.
Corresponding Author
Harry Struijker-Boudier
Received 19 December 2016, Accepted 2 April 2017, Available Online 21 April 2017.
- DOI
- 10.1016/j.artres.2017.04.001How to use a DOI?
- Keywords
- Statin; Hypertension; Cardiovascular risk reduction
- Abstract
Statins have become an essential treatment for primary and secondary prevention of cardiovascular risk. This has been firmly established for patients with a relatively high risk for cardiovascular complications. Recent studies, in particular the HOPE trial, has extended this observation to patients with intermediate cardiovascular risk, including hypertensive patients. On the other hand, statin use has been associated with side effects in a small percentage of patients. The decision to add a statin to the drug treatment of a hypertensive patient should be based on an assessment of the individual’s potential risk reduction and the perceived side effects of the treatment.
- Copyright
- © 2017 Association for Research into Arterial Structure and Physiology. Published by Elsevier B.V. All rights reserved.
- Open Access
- This is an open access article distributed under the CC BY-NC license.
Download article (PDF)
View full text (HTML)
Cite this article
TY - JOUR AU - Harry Struijker-Boudier PY - 2017 DA - 2017/04/21 TI - Should a statin be given to all hypertensive patients? JO - Artery Research SP - 66 EP - 68 VL - 18 IS - C SN - 1876-4401 UR - https://doi.org/10.1016/j.artres.2017.04.001 DO - 10.1016/j.artres.2017.04.001 ID - Struijker-Boudier2017 ER -